Thursday 22 January 2026, 12pm GMT
Hilco is seeking offers to acquire the intellectual property assets of Cognetivity Limited (In Administration) (“Cognetivity” or the “Company”) on behalf of the Joint Administrators of the Company, Paul Atkinson and Julie Humphrey of FRP Advisory Trading Limited.
Founded in 2013 as a spin-out from the University of Cambridge, Cognetivity was established in response to the limitations of traditional dementia diagnostic methods, many of which have remained largely unchanged for decades. Building on cutting-edge computational neuroscience research, the Company developed a proprietary Integrated Cognitive Assessment (CognICA) platform that uses artificial intelligence to provide a faster, more objective and scalable measurement of brain function, designed to move beyond language and education-dependent cognitive tests, enabling earlier and more accurate detection of cognitive impairment in real-world clinical settings.
The product of over a decade of research and development and supported by more than $15 million of investment, Cognetivity built a clinically validated, AI-driven cognitive assessment platform designed for use across regulated healthcare environments. The Company’s flagship product, CognICA, is an image-based cognitive test delivered via standard consumer hardware and supported by proprietary artificial intelligence and machine-learning models. CognICA was developed to support early detection and monitoring of neurological conditions including Alzheimer’s disease and other dementias, as well as broader brain-health and mental-health use cases. The Company also developed tools to allow CognICA to be integrated into third-party digital health and medical technology platforms.
Unlike legacy cognitive assessments, CognICA was designed to be language-agnostic, resistant to learning bias and suitable for repeated use, making it particularly well suited to population-level screening, longitudinal monitoring and clinical-trial applications. The Company’s platform achieved a strong regulatory position, including FDA registration, CE marking, MHRA approval, and approvals in Canada and Australia, enabling deployment across multiple international healthcare markets.
The Company focused on delivering its technology to institutional and professional customers, including neurology and psychiatry clinics, specialist memory services, private healthcare providers, and pharmaceutical and life-sciences organisations. Early commercial traction was achieved through pilot deployments and paid contracts in the UK, the US, the Middle East and Asia, alongside advanced discussions and accepted tenders for larger-scale rollouts.
This acquisition represents an opportunity to secure a fully developed, clinically validated cognitive-assessment platform and associated IP, providing a purchaser with a solid foundation to re-enter discussions with healthcare providers, life-sciences organisations and technology partners, accelerate commercialisation in a growing brain-health market, and establish a differentiated position in early cognitive-impairment detection and monitoring.
Cognetivity established itself as a clinically focused and research-led player in the digital health and cognitive assessment landscape. The Cognetivity and CognICA brands are closely associated with objective, AI-driven measurement of brain function, underpinned by strong scientific foundations, regulatory credibility and peer recognition within the healthcare and life-sciences communities.
The credibility of the Cognetivity brand has been reinforced through a combination of regulatory approvals, peer-reviewed validation and industry recognition. The CognICA platform achieved approval across multiple major jurisdictions and received high-profile innovation awards, including recognition at leading AI and healthcare technology forums. Further, the Company’s successful collaborations, pilots and deployments with specialist clinics, healthcare providers and life-sciences organisations have further strengthened the brand’s standing.
For an acquirer, the Cognetivity and CognICA brand identities provide a trusted and well-positioned entry point into the rapidly growing brain-health and cognitive-assessment market.
The Company holds a portfolio of registered trade marks and pending applications covering the “Cognetivity”, “CognICA” and related brand names.
Full details of the Company’s trade marks are available via a virtual data room.
Cognetivity developed and protected its core technology through a global patent portfolio focused on objective, technology-enabled assessment of brain function and cognitive impairment.
The Company’s patents centre on systems and methods for assessing neurological and mental health conditions using image-based cognitive testing and AI-driven analysis, forming the technical foundation of the CognICA platform. The Company’s portfolio includes a granted international patent family, with protection secured across multiple major jurisdictions, including the US, Europe and key international markets.
In addition to granted patents, the Company’s portfolio includes pending applications covering extensions of the core technology, including methods for predicting brain biomarker status and related diagnostic applications. Together, these filings provide layered protection around the Company’s proprietary approach, supporting both direct clinical use and potential integration into third-party healthcare and life-sciences platforms.
The Company’s software offering centres on CognICA, the Company’s flagship AI-driven cognitive assessment platform, which represents more than a decade of research, development and clinical validation.
At its core, CognICA is an image-based cognitive assessment system delivered via standard consumer hardware and supported by proprietary artificial-intelligence and machine-learning models, designed to quickly assess cognitive performance, analyse response patterns, and generate meaningful insights to support early detection and monitoring of cognitive impairment. Unlike traditional cognitive tests, the software is language-agnostic, resistant to learning effects, and suitable for repeat use.
Acquiring Cognetivitity’s software offers the chance to secure a mature, clinically validated and regulation-ready platform, offering a substantial head start in the development of AI-enabled cognitive assessment solutions, without the multi-year investment typically required to build, validate and certify a similar solution from scratch.
The Company holds a substantial body of proprietary know-how and trade secrets, including core software code, algorithms for selecting and sequencing natural images, and extensive clinical, research and real-world datasets generated through trials and deployments. The Company also holds regulatory and operational know-how, as well as proprietary health-economics models for both the UK and US markets.
The Company holds the cognetivity.com domain, which is available to acquire.
The Company also likely owns the copyright in the website content hosted at its domain, showcasing the CognICA platform, its clinical use cases and applications within healthcare and life-sciences environments.
Rights in social media accounts are also available to acquire across Twitter and LinkedIn.
Full details on the Company’s social media accounts are available via a virtual data room.
The Company holds a database of historic and prospective customers, clinical partners and key industry contacts, such as healthcare providers, specialist clinics, life-sciences organisations and technology partners engaged through pilots, commercial discussions and tender processes.
The deadline for offers is Thursday 22 January 2026 at 12pm GMT
All expressions of interest and bids are to be directed to Hilco in writing. A Bid Submission Form is available on request. Please contact Hilco to gain access to a virtual data room for further information on signing a confidentiality agreement.
Hilco is acting as exclusive agent to the Company and its Joint Administrators in connection with the proposed sale of some or all of the Company’s assets. The Joint Administrators act as agents of the Company and without personal liability.
All sales are made strictly on an “as is, where is” basis. Only such right, title and interest (if any) as the Company may have in the assets will be transferred to a purchaser. No warranties, guarantees, or representations (express or implied) are provided by the Company, its Joint Administrators, or Hilco in respect of the assets or any information supplied. All parties must rely on their own enquiries and due diligence. Any information provided is for convenience only and has not been independently verified.
All offers are subject to the addition of VAT at the prevailing rate, where applicable. A non-refundable deposit equal to 20% of the agreed purchase price must be paid by the successful purchaser within 48 hours of offer acceptance. Payment of the deposit grants the purchaser the exclusive right to proceed with the acquisition of the relevant assets for a limited period and on the terms agreed. A Buyer’s Premium of 10% of the final purchase price is payable by the successful purchaser in addition to the agreed purchase price, is non-negotiable and is payable at the same time and in the same manner as the purchase price and forms a condition of sale.
Legal completion must occur within five (5) business days of offer acceptance, unless otherwise agreed in writing by the Company and its Joint Administrators.
